Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.8 AUD | +2.86% | +2.86% | -6.49% |
Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 24.61M | Sales 2025 * | 60.9M 40.08M | Capitalization | 170M 112M |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.32M | Net income 2025 * | 11M 7.24M | EV / Sales 2024 * | 4.53 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.78 x |
P/E ratio 2024 * |
-71.9
x | P/E ratio 2025 * |
14.7
x | Employees | 87 |
Yield 2024 * |
0.56% | Yield 2025 * |
3.39% | Free-Float | 45.15% |
1 day | +2.86% | ||
1 week | +2.86% | ||
Current month | +0.28% | ||
1 month | +1.12% | ||
3 months | +0.84% | ||
6 months | -7.69% | ||
Current year | -6.49% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
Mathew Farag
COO | Chief Operating Officer | - | 16-12-31 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 19-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 21-08-09 |
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
David Heaney
CHM | Chairman | 79 | 06-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1.8 | +2.86% | 2,610,663 |
24-04-30 | 1.75 | -0.57% | 16,847 |
24-04-29 | 1.76 | +0.57% | 7,385 |
24-04-26 | 1.75 | 0.00% | 220 |
Delayed Quote Australian S.E., May 02, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.49% | 111M | |
+7.62% | 218B | |
+6.70% | 183B | |
+11.94% | 134B | |
+24.60% | 106B | |
-1.67% | 61.12B | |
+4.81% | 50.89B | |
+11.55% | 51.26B | |
-1.09% | 40.3B | |
+26.82% | 32.05B |
- Stock Market
- Equities
- CYC Stock